20 results about "Dextromethorphan Hydrobromide" patented technology

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The present disclosure relates to a method of treating depression and / or reducing the risk of suicide comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride (or a molar equivalent of bupropion in another form) and about 40 mg to about 50 mg of dextromethorphan hydrobromide (or a molar equivalent of dextromethorphan in another form). The combination can be administered twice a day to a person with major depressive disorder and a score of 3 or higher on the suicide ideation item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI).

The application belongs to the field of pharmaceutical chemistry and particularly relates to a preparation method of dextromethorphan hydrobromide. The method comprises the following steps: adding a reducing agent to a solution containing a compound of formula 3, adding an acid, performing a reduction reaction, obtaining a boron-containing intermediate state, and performing acid hydrolysis on the boron-containing intermediate state to obtain dextromethorphan. In the reduction reaction process for preparing dextromethorphan, sodium borohydride and an acid system are adopted, and compared with a sodium borohydride and zinc chloride system, the reaction is more complete, and the yield and purity of dextromethorphan are greatly improved. In the process for preparing dextromethorphan hydrobromide, butanone is used as a solvent, and compared with other solvents, butanone has the best refining effect, and related impurities can be effectively removed.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The invention relates to a dextromethorphan hydrobromide quinidine sulfate capsule and a preparation method thereof. The dextromethorphan hydrobromide quinidine sulfate capsule comprises dextromethorphan hydrobromide, quinidine sulfate, a filling agent, a disintegrating agent, a flow aid, a lubricating agent and a capsule shell. The preparation process comprises the following steps: uniformly mixing the active ingredients with part of the auxiliary materials, preparing into particles through dry granulation, adding the lubricant, mixing, and filling into capsules. According to the dextromethorphan hydrobromide quinidine sulfate capsule and the preparation method thereof, the novel crystal form of quinidine sulfate found and disclosed for the first time is adopted, under the specific prescription, the stability of a preparation composition is improved and is kept consistent with the dosage form of an original research medicine, meanwhile, the dextromethorphan hydrobromide quinidine sulfate capsule provided by the invention is simple in preparation process, the quality of products between batches and in batches is stable, and the dextromethorphan hydrobromide quinidine sulfate capsule is suitable for industrial mass production.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having severe renal impairment.

This disclosure relates to dosage forms comprising: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of dextromethorphan; and 2) about 25-35 mg, about 29-31 mg, about 30 mg, about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan. In some embodiments, a dosage form as described herein is free of a Compound I and Compound II. In some embodiments, a dosage form may contain 0.5 ng to 750 ng of Compound I, 0.5 ng to 750 ng of Compound II, or a combination thereof. These dosage forms may be used to treat various neurological and psychiatric conditions, including major depressive disorder, agitation associated with Alzheimer's disease, and nicotine addiction.

This disclosure relates to a method of treating depression and / or reducing suicide risk, comprising administering a combination of about 90 mg to about 120 mg of bupropion chloride (or another molar equivalent of bupropion) and about 40 mg to about 50 mg of dextromethorphan hydrobromide (or another molar equivalent of dextromethorphan). This combination can be administered twice daily to individuals suffering from severe depression and scoring 3 or higher on the Suicide Proneness Item of the Montgomery-Aussberg Depression Rating Scale (MADRS-SI).

This disclosure relates to the administration of the following combinations in certain patient populations: 1) about 100–110 mg, about 104–106 mg, or about 105 mg or less of bupropion hydrochloride or a molar equivalent of the free base form or another salt form of bupropion; and 2) about 40–50 mg, about 44–46 mg, or about 45 mg or less of dextromethorphan hydrobromide or a molar equivalent of the free base form or another salt form of dextromethorphan, in patient populations such as patients with moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients known to be poor CYP2D6 metabolizers, patients requiring an NMDA antagonist that does not cause dissociation, and patients at risk of QT prolongation.

This disclosure relates to the administration of the following combinations: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride or a molar equivalent of bupropion in its free base form or another salt form; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide or a molar equivalent of dextromethorphan in its free base form or another salt form.

The present disclosure relates to administering in certain patient populations a combination of: 1) bupropion hydrochloride or bupropion in a molar equivalent amount in the form of a free base or in the form of another salt in a range of about 100 to 110 mg, about 104 to 106 mg, or about 105 mg; and 2) dextromethorphan hydrobromide or a molar equivalent amount of dextromethorphan in the form of a free base or in the form of another salt, in the range of from about 40 to 50 mg, from about 44 to 46 mg, or from about 45 mg, the present invention relates to certain populations of patients, such as patients suffering from moderate renal injury, patients receiving companion strong CYP2D6 inhibitors, patients known to be CYP2D6 weak metabolites, patients in need of NMDA antagonists that do not cause dissociation, and patients at risk of QT extension.

This disclosure relates to a method of treating depression and / or reducing suicide risk, comprising administering a combination of about 90 mg to about 120 mg of bupropion chloride (or another molar equivalent of bupropion) and about 40 mg to about 50 mg of dextromethorphan hydrobromide (or another molar equivalent of dextromethorphan). This combination can be administered twice daily to individuals suffering from severe depression and scoring 3 or higher on the Suicide Proneness Item of the Montgomery-Aussberg Depression Rating Scale (MADRS-SI).

This disclosure relates to a method of treating depression and / or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The application belongs to the field of pharmaceutical chemistry and particularly relates to a preparation method of dextromethorphan hydrobromide. The method comprises the following steps: adding a reducing agent to a solution containing a compound of formula 3, adding an acid, performing a reduction reaction, obtaining a boron-containing intermediate state, and performing acid hydrolysis on the boron-containing intermediate state to obtain dextromethorphan. In the reduction reaction process for preparing dextromethorphan, sodium borohydride and an acid system are adopted, and compared with a sodium borohydride and zinc chloride system, the reaction is more complete, and the yield and purity of dextromethorphan are greatly improved. In the process for preparing dextromethorphan hydrobromide, butanone is used as a solvent, and compared with other solvents, butanone has the best refining effect, and related impurities can be effectively removed.